The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections.
Arnon
R
R
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
D000818:Animals; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects / Q000138:chemical synthesis / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*
D010455:Peptides; C021759:(T,G)-A-L